Cargando…
Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study
Background: Pathologic changes in cortical gray matter (GM) and leptomeninges contribute to disability worsening in patients with multiple sclerosis (MS), but there is little evidence whether disease-modifying treatments can slow down cortical pathology in MS. Objectives: To investigate the effect o...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463015/ https://www.ncbi.nlm.nih.gov/pubmed/30870983 http://dx.doi.org/10.3390/jcm8030344 |
_version_ | 1783410681909870592 |
---|---|
author | Zivadinov, Robert Bergsland, Niels Carl, Ellen Ramasamy, Deepa P. Hagemeier, Jesper Dwyer, Michael G. Lizarraga, Alexis A. Kolb, Channa Hojnacki, David Weinstock-Guttman, Bianca |
author_facet | Zivadinov, Robert Bergsland, Niels Carl, Ellen Ramasamy, Deepa P. Hagemeier, Jesper Dwyer, Michael G. Lizarraga, Alexis A. Kolb, Channa Hojnacki, David Weinstock-Guttman, Bianca |
author_sort | Zivadinov, Robert |
collection | PubMed |
description | Background: Pathologic changes in cortical gray matter (GM) and leptomeninges contribute to disability worsening in patients with multiple sclerosis (MS), but there is little evidence whether disease-modifying treatments can slow down cortical pathology in MS. Objectives: To investigate the effect of teriflunomide (TFM) and dimethyl fumarate (DMF) in reducing cortical pathology, as determined by percentage cortical volume change (PCVC) and leptomeningeal contrast enhancement (LMCE) on MRI. Methods: This was a retrospective, single-center, observational study that selected 60 TFM- and 60 DMF-treated MS patients over 24 months. Results: TFM had a lower rate of PCVC compared to DMF over 24 months (−0.2% vs. −2.94%, p = 0.004). Similar results were observed for percentage GM volume change over 0–12 (p = 0.044) and 0–24 (−0.44% vs. −3.12%, p = 0.015) months. No significant differences were found between the TFM and DMF groups in the frequency and number of LMCE foci over the follow-up. TFM showed a numerically lower rate of whole brain atrophy over 24 months (p = 0.077), compared to DMF. No significant clinical or MRI lesion differences between TFM and DMF were detected over follow-up. Conclusions: These findings suggest that TFM has a superior effect on the preservation of cortical GM volume, compared to DMF. |
format | Online Article Text |
id | pubmed-6463015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64630152019-04-19 Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study Zivadinov, Robert Bergsland, Niels Carl, Ellen Ramasamy, Deepa P. Hagemeier, Jesper Dwyer, Michael G. Lizarraga, Alexis A. Kolb, Channa Hojnacki, David Weinstock-Guttman, Bianca J Clin Med Article Background: Pathologic changes in cortical gray matter (GM) and leptomeninges contribute to disability worsening in patients with multiple sclerosis (MS), but there is little evidence whether disease-modifying treatments can slow down cortical pathology in MS. Objectives: To investigate the effect of teriflunomide (TFM) and dimethyl fumarate (DMF) in reducing cortical pathology, as determined by percentage cortical volume change (PCVC) and leptomeningeal contrast enhancement (LMCE) on MRI. Methods: This was a retrospective, single-center, observational study that selected 60 TFM- and 60 DMF-treated MS patients over 24 months. Results: TFM had a lower rate of PCVC compared to DMF over 24 months (−0.2% vs. −2.94%, p = 0.004). Similar results were observed for percentage GM volume change over 0–12 (p = 0.044) and 0–24 (−0.44% vs. −3.12%, p = 0.015) months. No significant differences were found between the TFM and DMF groups in the frequency and number of LMCE foci over the follow-up. TFM showed a numerically lower rate of whole brain atrophy over 24 months (p = 0.077), compared to DMF. No significant clinical or MRI lesion differences between TFM and DMF were detected over follow-up. Conclusions: These findings suggest that TFM has a superior effect on the preservation of cortical GM volume, compared to DMF. MDPI 2019-03-12 /pmc/articles/PMC6463015/ /pubmed/30870983 http://dx.doi.org/10.3390/jcm8030344 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zivadinov, Robert Bergsland, Niels Carl, Ellen Ramasamy, Deepa P. Hagemeier, Jesper Dwyer, Michael G. Lizarraga, Alexis A. Kolb, Channa Hojnacki, David Weinstock-Guttman, Bianca Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study |
title | Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study |
title_full | Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study |
title_fullStr | Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study |
title_full_unstemmed | Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study |
title_short | Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study |
title_sort | effect of teriflunomide and dimethyl fumarate on cortical atrophy and leptomeningeal inflammation in multiple sclerosis: a retrospective, observational, case-control pilot study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463015/ https://www.ncbi.nlm.nih.gov/pubmed/30870983 http://dx.doi.org/10.3390/jcm8030344 |
work_keys_str_mv | AT zivadinovrobert effectofteriflunomideanddimethylfumarateoncorticalatrophyandleptomeningealinflammationinmultiplesclerosisaretrospectiveobservationalcasecontrolpilotstudy AT bergslandniels effectofteriflunomideanddimethylfumarateoncorticalatrophyandleptomeningealinflammationinmultiplesclerosisaretrospectiveobservationalcasecontrolpilotstudy AT carlellen effectofteriflunomideanddimethylfumarateoncorticalatrophyandleptomeningealinflammationinmultiplesclerosisaretrospectiveobservationalcasecontrolpilotstudy AT ramasamydeepap effectofteriflunomideanddimethylfumarateoncorticalatrophyandleptomeningealinflammationinmultiplesclerosisaretrospectiveobservationalcasecontrolpilotstudy AT hagemeierjesper effectofteriflunomideanddimethylfumarateoncorticalatrophyandleptomeningealinflammationinmultiplesclerosisaretrospectiveobservationalcasecontrolpilotstudy AT dwyermichaelg effectofteriflunomideanddimethylfumarateoncorticalatrophyandleptomeningealinflammationinmultiplesclerosisaretrospectiveobservationalcasecontrolpilotstudy AT lizarragaalexisa effectofteriflunomideanddimethylfumarateoncorticalatrophyandleptomeningealinflammationinmultiplesclerosisaretrospectiveobservationalcasecontrolpilotstudy AT kolbchanna effectofteriflunomideanddimethylfumarateoncorticalatrophyandleptomeningealinflammationinmultiplesclerosisaretrospectiveobservationalcasecontrolpilotstudy AT hojnackidavid effectofteriflunomideanddimethylfumarateoncorticalatrophyandleptomeningealinflammationinmultiplesclerosisaretrospectiveobservationalcasecontrolpilotstudy AT weinstockguttmanbianca effectofteriflunomideanddimethylfumarateoncorticalatrophyandleptomeningealinflammationinmultiplesclerosisaretrospectiveobservationalcasecontrolpilotstudy |